Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Research analysts at Wedbush decreased their Q1 2019 EPS estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, November 7th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings per share of $0.02 for the quarter, down from their previous estimate of $0.03. Wedbush currently has a “Neutral” rating on the stock. Wedbush also issued estimates for Ironwood Pharmaceuticals’ Q2 2019 earnings at $0.16 EPS.
IRWD has been the topic of a number of other research reports. BidaskClub downgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th. Wells Fargo & Co set a $23.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 8th. HC Wainwright began coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, July 23rd. They issued a “sell” rating and a $12.50 price target on the stock. BTIG Research set a $17.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday. Finally, ValuEngine downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 31st. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $17.35.
Shares of NASDAQ IRWD opened at $11.88 on Friday. The company has a market capitalization of $1.83 billion, a PE ratio of -12.77 and a beta of 1.33. Ironwood Pharmaceuticals has a 52-week low of $11.62 and a 52-week high of $21.20.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.24). The firm had revenue of $68.69 million for the quarter, compared to analysts’ expectations of $93.48 million. The business’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.18) EPS.
In other news, insider Mark G. Currie sold 130,000 shares of Ironwood Pharmaceuticals stock in a transaction on Thursday, August 23rd. The shares were sold at an average price of $18.45, for a total value of $2,398,500.00. Following the completion of the sale, the insider now owns 791,666 shares in the company, valued at approximately $14,606,237.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Julie Mchugh sold 1,500 shares of Ironwood Pharmaceuticals stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $19.10, for a total transaction of $28,650.00. Following the completion of the sale, the director now owns 91,131 shares of the company’s stock, valued at approximately $1,740,602.10. The disclosure for this sale can be found here. Insiders sold a total of 248,339 shares of company stock valued at $4,475,466 in the last quarter. 7.63% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. OppenheimerFunds Inc. increased its stake in shares of Ironwood Pharmaceuticals by 11.1% in the 2nd quarter. OppenheimerFunds Inc. now owns 2,872,640 shares of the biotechnology company’s stock valued at $54,925,000 after acquiring an additional 286,590 shares in the last quarter. Aperio Group LLC increased its stake in shares of Ironwood Pharmaceuticals by 34.2% in the 2nd quarter. Aperio Group LLC now owns 21,185 shares of the biotechnology company’s stock valued at $405,000 after acquiring an additional 5,404 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at $186,000. Schwab Charles Investment Management Inc. increased its stake in shares of Ironwood Pharmaceuticals by 6.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 722,555 shares of the biotechnology company’s stock valued at $13,816,000 after acquiring an additional 44,157 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its stake in shares of Ironwood Pharmaceuticals by 11.3% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 120,370 shares of the biotechnology company’s stock valued at $2,301,000 after acquiring an additional 12,175 shares in the last quarter. Institutional investors own 97.29% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
See Also: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.